Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.

Zeitlberger, A M; Putora, P M; Hofer, S; Schucht, P; Migliorini, D; Hottinger, A F; Roelcke, U; Läubli, H; Spina, P; Bozinov, O; Weller, M; Neidert, M C; Hundsberger, T (2022). Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis. Journal of neuro-oncology, 158(3), pp. 359-367. Springer 10.1007/s11060-022-04022-7

[img] Text
s11060-022-04022-7.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (816kB)

BACKGROUND

Glioblastoma is the most common malignant primary brain tumour in adults and driven by various genomic alterations. Next generation sequencing (NGS) provides timely information about the genetic landscape of tumours and might detect targetable mutations. To date, differences exist in the application and NGS assays used as it remains unclear to what extent these variants may affect clinical decision making. In this survey-based study, we investigated the use of NGS in adult patients with glioblastoma in Switzerland.

METHODS

All eight primary care centres for Neuro-Oncology in Switzerland participated in this survey. The NGS assays used as well as the criteria for the application of NGS in newly diagnosed glioblastoma were investigated. Decision trees were analysed for consensus and discrepancies using the objective consensus methodology.

RESULTS

Seven out of eight centres perform NGS in patients with newly diagnosed glioblastoma using custom made or commercially available assays. The criteria most relevant to decision making were age, suitability of standard treatment and fitness. NGS is most often used in fitter patients under the age of 60 years who are not suitable for standard therapy, while it is rarely performed in patients in poor general health.

CONCLUSION

NGS is frequently applied in glioblastomas in adults in Neuro-Oncology centres in Switzerland despite seldom changing the course of treatment to date.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurosurgery

UniBE Contributor:

Schucht, Philippe

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0167-594X

Publisher:

Springer

Language:

English

Submitter:

Andrea Stettler

Date Deposited:

30 Nov 2022 07:48

Last Modified:

05 Dec 2022 16:29

Publisher DOI:

10.1007/s11060-022-04022-7

PubMed ID:

35486306

Uncontrolled Keywords:

Diagnostics Glioblastoma Glioma Next generation sequencing

BORIS DOI:

10.48350/175334

URI:

https://boris.unibe.ch/id/eprint/175334

Actions (login required)

Edit item Edit item
Provide Feedback